Starpharma Hldgs ADR (SPHRY) 5.5200 $SPHRY
Australian Olympic Team Taking Dual Protect(TM) VivaGel(R) Condoms to Rio
BusinessWire - Sun May 15, 11:32PM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) and Ansell Limited (ASX:ANN) today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect(TM) VivaGel(R) condoms for the upcoming Olympic Games in Rio de Janeiro.
ANN: 44.89 (-0.16)
VivaGel Active against Zika Virus
BusinessWire - Thu May 05, 7:15PM CDT
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel(R) active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel(R) condom.
Starpharma's Targeted DEP(TM) Outperforms Leading Treatments in Ovarian Cancer Model
BusinessWire - Mon Nov 16, 6:00AM CST
Starpharma (ASX: SPL) (OTCQX: SPHRY) today announced that treatment with its novel antibody-targeted DEP(R) conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
CDXC: 5.76 (+0.20)
EU Marketing Approval Granted for VivaGel(R) BV
BusinessWire - Thu Sep 24, 6:00AM CDT
Starpharma (ASX: SPL) (OTCQX: SPHRY) today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel(R) BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.
Starpharma Signs Drug Delivery License with AstraZeneca
BusinessWire - Mon Sep 07, 12:04AM CDT
--Under the agreement Starpharma will receive a signature payment of US$2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP(R) product of USD$124 million (A$177 million).
Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 44.89 (-0.16)
Australian Olympic Team Taking Dual Protect(TM) VivaGel(R) Condoms to Rio
BusinessWire - Sun May 15, 11:32PM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) and Ansell Limited (ASX:ANN) today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect(TM) VivaGel(R) condoms for the upcoming Olympic Games in Rio de Janeiro.
ANN: 44.89 (-0.16)
VivaGel Active against Zika Virus
BusinessWire - Thu May 05, 7:15PM CDT
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel(R) active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel(R) condom.
Starpharma's Targeted DEP(TM) Outperforms Leading Treatments in Ovarian Cancer Model
BusinessWire - Mon Nov 16, 6:00AM CST
Starpharma (ASX: SPL) (OTCQX: SPHRY) today announced that treatment with its novel antibody-targeted DEP(R) conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
CDXC: 5.76 (+0.20)
EU Marketing Approval Granted for VivaGel(R) BV
BusinessWire - Thu Sep 24, 6:00AM CDT
Starpharma (ASX: SPL) (OTCQX: SPHRY) today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel(R) BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.
Starpharma Signs Drug Delivery License with AstraZeneca
BusinessWire - Mon Sep 07, 12:04AM CDT
--Under the agreement Starpharma will receive a signature payment of US$2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP(R) product of USD$124 million (A$177 million).
Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 44.89 (-0.16)
